Whooping cough cases confirmed in Carteret County Schools
CARTERET COUNTY, N.C. (WNCT)- The Carteret County Health Department has confirmed cases of pertussis (whooping cough) in the county including at two schools.
The schools include Broad Creek Middle School and Croatan High School. Public Health Nurse Director Kim Davis says they are working closely with schools through notifying parents of potential exposures and providing guidance on symptoms and prevention. High risk students who were exposed could be advised to take preventive antibiotics
Whooping cough is highly contagious and can be very serious, especially for infants and people with chronic illnesses. Symptoms include runny nose, worsening cough or 'whooping' sounds. Children with these symptoms should stay home from school and call their health care provider.
Vaccination is the best way to prevent whooping cough. School age children should be up to date on DTap/Tdap vaccines, while older children and adults who haven't received a booster should contact their health care provider or the health department at 252-728-8550.
For more information on whooping cough and vaccines, visit CDC Pertussis Symptoms and CDC Vaccines.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
35 minutes ago
- Axios
Arkansas ranks low in 988 mental health hotline use
Arkansans are less likely to use the 988 national suicide prevention and mental health hotline than those in most states. Why it matters: The service was launched nearly three years ago to help address America's mental health crisis — but gaps persist. By the numbers: The hotline receives about 19.8 calls, texts and chats per 1,000 people in Arkansas, tying it for the 13th-lowest rate. Yes, but: Arkansas had the 18th-highest rate of suicide in 2022, according to the CDC. 547 people in Arkansas died of suicide, a rate of 18 per 100,000 people. Driving the news: Alaska (45.3 contacts per 1,000 people), Vermont (40.2) and New York (38.8) had the highest 988 contact rates among states in 2024, per new research published in JAMA Network Open. Delaware (12.5), Alabama (14.4) and Florida (15.6) had the lowest. The big picture: The 988 service fielded more than 16.3 million calls, texts and chats between July 2022 and the end of 2024. The national contact rate was 48.9 per 1,000 people during that period, and 23.7 in 2024 alone. How it works: "Contacts" include all calls, texts and chats sent to 988, including those forwarded along to more specific services, like the Veterans Crisis Line and the LGBTQ+ Line. Geography for calls and chats was assigned based on users' phone numbers, while texts were assigned by ZIP codes shared during pre-chat surveys. What they're saying: Several factors may be contributing to the state and regional differences in 988 use, says study author Jonathan Purtle, associate professor and director of policy research at New York University's School of Global Public Health. That includes differences in how 988 is being advertised by states and cities, as well as political attitudes. Many Americans remained unfamiliar with 988 as of last summer, per Ipsos polling. And surveys have found that Democrats are more likely than Republicans to use 988, Purtle says: "We see this shake out in the map — in the South and more right-leaning places, we see lower volume." Caveat: Less populous states have more variability due to their relatively smaller sample sizes, Purtle notes. The latest: The Trump administration's proposed Health and Human Services budget would cut 988 services specifically tailored for LGBTQ+ youth, Axios' Avery Lotz reports. What's next: Last year's nationwide 988 contact rate was less than half the rate of adult emergency room visits related to mental health, the analysis finds, despite ERs' cost and access issues.
Yahoo
an hour ago
- Yahoo
Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology
Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via 'patch' technology and utilizes Micron's first-in-class dissolvable microarray technology Research builds on Emory's research on influenza vaccines self-administered via Micron's microarray technology ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Emory University and Micron Biomedical today announced the first clinical trial of a novel rotavirus vaccine, CC24, delivered via dissolvable microarray technology is now enrolling participants. This marks the first clinical evaluation of any drug or vaccine delivered via patch or microarray that is sponsored by the U.S. Centers for Disease Control and Prevention (CDC). Rotavirus infection remains a leading cause of childhood diarrheal deaths, primarily in low- and middle-income countries where existing oral vaccines are less effective. CC24 is a uniquely inactivated rotavirus vaccine developed by the CDC to allow for an alternative to oral administration. 'CDC recognizes the potential of this groundbreaking clinical trial, which will test the safety of both our novel vaccine, CC24, in adults and the vaccine's delivery with 'patch' technology,' said Dr. Demetre Daskalakis, Director of CDC's National Center for Immunization and Respiratory Diseases. 'The trial marks significant progress in vaccine technology innovation and is a critical step toward saving more children from rotavirus illness and death.' Micron Biomedical's unique needle-free technology rapidly delivers vaccines and therapeutics via dissolvable microarray compounds that are pressed painlessly into the uppermost layers of skin. The company formulates existing drugs so that they have thermostable properties, reducing or eliminating the need for a cold chain, and packages them in a thumb-size lightweight technology so it can be self-administered with the push of a button, while producing no medical sharps waste. Micron's technology has been recognized for its potential to expand vaccine and therapeutic access in hard-to-reach settings, such as developing countries and where medicines need to be swiftly delivered and administered–such as in times of epidemics and pandemics, as well as national security applications and military uses. 'Rotavirus is a leading cause of diarrheal morbidity and mortality in children less than five years of age worldwide, but current oral rotavirus vaccines don't work as well in low- and middle-income countries where the burden of disease is greatest,' said 'With this trial we are thrilled to advance scientific innovations that have the potential to save lives, as well as significantly improve access and uptake of other vaccines globally and here in the U.S.' 'The availability of new vaccine administration methods, such as Micron Biomedical's dissolvable microarray patch, could offer important choices for children and adults, not just with rotavirus but also with vaccines that are currently administered by injection,' said 'People who are afraid of needles may be more likely to use this patch because it feels less invasive than vaccines currently administered by injection.' The study builds on existing research by Emory University, published in The Lancet, about self-administered seasonal influenza vaccine via Micron Biomedical's dissolvable microarray technology, as well as studies across other disease indications, including measles and rubella. 'The faster we can simplify access to life-saving vaccines and therapeutics, the more lives we can save and this clinical trial is a critical milestone both in accelerating innovations that are likely to make rotavirus vaccines more effective and accessible - and in demonstrating the growing demand for needle-free vaccines and drugs,' said Steven Damon, CEO of Micron Biomedical. 'We're thrilled to collaborate with Emory University, a leader in clinical research with a heritage of studying next-generation vaccines and cutting-edge technologies, and with the CDC, whose work to develop this novel vaccine and collaboration with Micron Biomedical to deliver it without needles has been ground-breaking.' This phase I double-blind placebo-controlled trial will assess the safety, reactogenicity, and immunogenicity of a novel inactivated rotavirus vaccine CC24 delivered via Micron Biomedical's microarray technology—which provides painless, needle-free administration and overcomes vaccine transport and storage infrastructure challenges associated with conventional vaccines. The trial will recruit 50 healthy adults, between ages 18 and 45 years old. Data from the study will inform planned studies in children. Emory University, located in Atlanta, Georgia, is a leading research university with one of the fastest-growing research enterprises in the nation. Emory is known for its highly recognized professional schools of medicine, public health, nursing, business, law, and theology, as well as for its advanced research facilities and a rapid expansion of research support in the health sciences. Emory University School of Medicine is best known for its research and treatment in infectious disease, brain health, heart disease, cancer, transplantation, orthopaedics, pediatrics, renal disease, ophthalmology, and geriatrics. Micron Biomedical is the leader in dissolvable microarray-based, drug and vaccine administration technology. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron's technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and/or receives funding from private and public pharmaceutical and biotech companies, the Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH, the Coalition for Epidemic Preparedness Innovations (CEPI), Biomedical Advanced Research and Development Authority (BARDA) and the Georgia Research Alliance. For more information visit Media Inquiries Micron Biomedical: Shira DerasmoCuttlefish Communications+1 917 280 2497pr@ Emory University:Lara Moore+1 470 384 1878lmoore@ CDCTo request a comment or interview, reporters may visit the link in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 hours ago
- The Hill
RFK Jr.'s vaccine moves raise fears ahead of next school year
Secretary of Health and Human Services Robert F. Kennedy Jr.'s decision to fire the Centers for Disease Control and Prevention's (CDC) entire vaccine board even as childhood vaccination rates drop is setting off alarm bells for next school year. Health officials worry about the ramifications of Kennedy's recent decisions and philosophy towards vaccines more generally as schools prepare for their first year with him at the helm of nation's health. Diseases that had been eradicated from the U.S. are returning, and experts warn of the need for schools to be vigilant and prepare for outbreaks among their student body. So far this year, there have been nearly 1,200 cases of measles reported in 34 states, quadruple the total from all of last year. And the CDC says vaccine coverage among kindergarteners for measles, mumps and rubella (MMR) is below the target 95 percent threshold. 'I think schools are going to have to rely on state level and national experts to help guide their policies. This means that the current CDC recommendations for school-based vaccinations are still the most reliable and evidence based,' said Lawrence Gostin, distinguished professor of global health law at Georgetown University. 'If the secretary changes the childhood vaccination schedule, and I think he is all but certain to do that soon, states should hold fast on the current recommendations and consult their own health departments for future guidance,' Gostin added. Kennedy replaced the 17-member Advisory Committee on Immunization Practices (ACIP) with eight new voting members, with some who are known for spreading vaccine misinformation. Robert W. Malone, one of the new members, also promoted the use of hydroxychloroquine and ivermectin during the COVID-19 pandemic. 'A clean sweep is needed to re-establish public confidence in vaccine science,' Kennedy wrote. 'The public must know that unbiased science—evaluated through a transparent process and insulated from conflicts of interest—guides the recommendations of our health agencies,' he added in a subsequent statement. After the initial measles outbreak in Texas, Kennedy made multiple appearances on Fox News where he downplayed the severity of the disease and gave questionable advice on treatments, including emphasizing the use of vitamin A. The Health secretary at first suggested natural immunity gained from having measles is more useful than the vaccine, though he later conceded the MMR shot is the 'most effective way' to prevent the disease. 'The changes at ACIP … were not unexpected, but they are jarring,' said Josh Michaud, senior expert in U.S. and global vaccine policy for KFF, a health policy research and news organization. Michaud fears that the firings and RFK Jr.'s vaccine skepticism will have a negative 'effect on parents who might have been on the fence about vaccinations or allow more space for policy-makers at the state and local level to change the rules about vaccinations.' Schools only have a few months to prepare as a reverse in vaccination trends is unlikely to occur in the near future. Research published this month by Johns Hopkins University in JAMA showed 1,600 counties around the country have vaccination rates below 91 percent, missing the 95 percent mark for herd immunity. The only states that have seen an increase in county-level immunizations are California, Massachusetts, Connecticut and New York. 'I believe that most, if not all, blue states will continue to have rigorous science based rules for vaccinating children as a condition of school entry. But many red states will follow RFK. Jr.'s advice,' Gostin said. 'In those states, parents should make sure that their children and family members are all up to date on currently recommended vaccinations. I don't think they should be reluctant to send their children to school or to have them wear masks. That is overkill,' he added. 'If they are fully vaccinated, children will be protected. If the child is immunocompromised, then extra precautions may be needed.' Schools will also need to review their policies on how to deal with outbreaks and potentially look at past advice — and not future federal guidance — for how to handle vaccine recommendations. 'I think it's really for schools as they are thinking about their policies, and the policies that many of these school districts have had for many, many years, in terms of the vaccination schedules, in terms of requirements around vaccinations — to really think about the importance of vaccinations for children and to follow the policies that have worked for many years,' said Neil Maniar, professor of public health practice at Northeastern University. Along with the rise in measles and growing 'risk for other infectious diseases,' schools may have to also contend 'higher rates of the flu and RSV and other communicable diseases' than in years past, Maniar said. 'So we really want to make sure that schools are putting forth policies that are designed to really promote the health and wellbeing of children and their families and others in the community,' he added.
